2023 update of Indian national association for study of the liver consensus on management of intermediate and advanced hepatocellular carcinoma: the Puri III …
Hepatocellular carcinoma (HCC) presents significant treatment challenges despite
considerable advancements in its management. The Indian National Association for the …
considerable advancements in its management. The Indian National Association for the …
Efficacy and safety analysis of TACE+ Donafenib+ Toripalimab versus TACE+ Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective …
H Lu, B Liang, X **a, C Zheng - BMC cancer, 2023 - Springer
Objective To compare the efficacy and safety of TACE combined with Donafenib and
Toripalimab versus TACE combined with Sorafenib in the treatment of unresectable …
Toripalimab versus TACE combined with Sorafenib in the treatment of unresectable …
Changing etiological spectrum of hepatocellular carcinoma in India—a systematic review and meta-analysis
Background Recent studies from both India and outside India have shown a change in the
etiological profile of hepatocellular carcinoma (HCC). We aimed to analyze the etiological …
etiological profile of hepatocellular carcinoma (HCC). We aimed to analyze the etiological …
Efficacy and prognostic factors of regorafenib in the treatment of BCLC stage C hepatocellular carcinoma after failure of the first-line therapy
B Xu, D Lu, K Liu, W Lv, J **ao, X Zhang… - Drug Design …, 2023 - Taylor & Francis
Purpose Regorafenib is a standard second-line treatment for hepatocellular carcinoma
(HCC). This study aimed to evaluate the efficacy and safety of regorafenib in the treatment of …
(HCC). This study aimed to evaluate the efficacy and safety of regorafenib in the treatment of …
[HTML][HTML] Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement
N Şener, A Yakupoğlu - Medicine, 2023 - journals.lww.com
Hepatocellular carcinoma (HCC) with portal vein tumor thrombus is considered an
advanced stage disease. Non-surgical local and systemic therapies are the only treatment …
advanced stage disease. Non-surgical local and systemic therapies are the only treatment …
Downstaging Hepatocellular Carcinoma before Transplantation: Role of Immunotherapy Versus Locoregional Approaches
J Lindemann, J Yu, MBM Doyle - Surgical Oncology Clinics, 2024 - surgonc.theclinics.com
Primary liver cancer was the third most common cause of death due to cancer worldwide in
2020, and it is estimated that more than 1 million people will develop liver cancer annually …
2020, and it is estimated that more than 1 million people will develop liver cancer annually …
Prognostic Evaluation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Patients Treated with Transarterial Chemoembolization Plus Molecular …
K Liu, J Dai, C Hou, D Lu, B Zhao, S Yin, G Wang… - Academic …, 2024 - Elsevier
Rationale and Objectives Transarterial chemoembolization (TACE) plus molecular targeted
therapies has emerged as the main approach for treating hepatocellular carcinoma (HCC) …
therapies has emerged as the main approach for treating hepatocellular carcinoma (HCC) …
Sorafenib combined with TACE improves survival in patients with hepatocellular carcinoma with vascular invasion
Z Han, R Han, Y Wang, K Zhu, X Tian, P Chen… - BioScience …, 2024 - jstage.jst.go.jp
Sorafenib is a recommended first-line therapy for advanced hepatocellular carcinoma
(HCC). However, when used as monotherapy in patients in advanced stages, the prognosis …
(HCC). However, when used as monotherapy in patients in advanced stages, the prognosis …
[HTML][HTML] Efficacy of Transarterial Chemoembolization Combined With Camrelizumab in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta …
FAA Tashrifwala, VK Karmani, I Haider, AZ Syeda… - Cureus, 2023 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common primary cancer of liver tissue and is
often caused by chronic liver diseases. The Barcelona Clinic Liver Cancer (BCLC) staging …
often caused by chronic liver diseases. The Barcelona Clinic Liver Cancer (BCLC) staging …
The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma
A Olbrich, J Niemeyer, H Seiffert, S Ebel, O Gros… - Journal of Cancer …, 2024 - Springer
Purpose The GALAD score and the BALAD-2 score are biomarker-based scoring systems
used to detect hepatocellular carcinoma (HCC). Both incorporate levels of alpha-fetoprotein …
used to detect hepatocellular carcinoma (HCC). Both incorporate levels of alpha-fetoprotein …